This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Cramer's 'Mad Money' Recap: Running the Gauntlet

One of the company's moves was into areas where its competition wasn't: areas like Africa, Southeast Asia and Colombia in Central America. Sanofi also expanded into animal health, both for pets and animals used for food production. Both of those businesses are constant performers, noted Viehbacher.

Another area of interest was in treating the nearly 7,000 rare diseases that afflict humans. Medical science currently only treats 300 of them, said Viehbacher, leaving many so-called "orphan drugs" to be developed. One of those drugs is Kynamro, being developed in conjunction with Isis Pharmaceuticals (ISIS), which came under fire for safety concerns. Viehbacher called Isis a terrific partner and said Kynamro provides a significant benefit to patients but will need to be monitored further.

Finally, when asked about the rampant diabetes epidemic that affects 350 million people around the globe, Viehbacher said that while people will spend $100,000 to treat this life-long disease, they haven't spent $1 working to prevent it, something that he hopes one day to change.

Cramer said Sanofi is one stock that's not done going higher.

Lightning Round

In the Lightning Round, Cramer was bullish on Nike (NKE), LinnCo (LNCO), CenturyLink (CTL), Verizon (VZ), Forest Laboratories (FRX) and Royal Caribbean Cruises (RCL).

Cramer was bearish on Under Armour (UA), AT&T (T), BP Prudhoe Bay Royalty Trust (BPT) and Windstream (WIN).

On the Right Side of Expectations

For his final "Executive Decision" segment, Cramer spoke with Abhi Talwalkar, president and CEO of LSI Corp (LSI), a company on the right side of the expectations game. Its shares rose 7% Thursday after the company reported in-line results.

Talwalkar said investors were fearing the worst from LSI, but the company is further along in its transition away from PCs and into cloud and data center infrastructure. He said LSI owns the base station, which is where all mobile devices must first connect to for their data. LSI has proprietary technology that helps network data get to where it needs to go.

Talwalkar said that while all of technology spending is constrained at the moment, there is still a lot of great new technology being developed, which will eventually lead to a strong tech cycle going forward. He said data are being generated no matter what the economy, which is why LSI's products will always be in demand.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs